Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
StemRIM Inc. ( (JP:4599) ) just unveiled an announcement.
StemRIM Inc. has extended its joint research agreement with Shiseido and Osaka University to further study the mechanisms of skin stem cell aging. This research aims to develop innovative pharmaceuticals and cosmetics for skin anti-aging, with the extension expected to enhance company performance in the medium to long term without impacting short-term financial results.
More about StemRIM Inc.
StemRIM Inc. is a biotech venture originating from Osaka University, focusing on ‘Regeneration-Inducing Medicine’ which aims to enable regenerative therapy effects through drug administration without using living cells or tissues. The company is developing advanced regenerative medicine products to treat various diseases by mobilizing mesenchymal stem cells to damaged tissues to promote repair and regeneration.
YTD Price Performance: -1.59%
Average Trading Volume: 164,672
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen19.16B
See more insights into 4599 stock on TipRanks’ Stock Analysis page.
